Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Novartis
Age
18–85
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Patients must give written informed consent
Male or female ages 18 or older and less than 86 years
Diagnosed as having essential diastolic hypertension, as follows:
* Visit 2/Single-blind run-in entry, all participants MUST have a MSDBP ≥ 95 mmHg and \< 100 mmHg
* At Visit 3/Core double-blind treatment period entry, all patients MUST have a MSDBP \>=90 mmHg and \<110 mmHg
You may not be if
Severe hypertension
Evidence of secondary form of hypertension (coarctation of the aorta, hyperaldosteronism, unilateral or bilateral renal artery stenosis, Cushing's disease, pheochromocytoma or polycystic kidney disease )
Malignant hypertension
Administration of any agent indicated for the treatment of hypertension after Visit 1
Known moderate or malignant retinopathy.
Known or suspected contraindications, including history of allergy or hypersensitivity to Angiotensin II Receptor Blockers (ARBs), Calcium Channel Blockers (CCBs), or to drugs with similar chemical structures
History of hypertensive encephalopathy, cerebrovascular accident, or transient ischemic attack, myocardial infarction or all types of revascularization, angina pectoris of any type, including unstable angina
History of heart failure Grade II-IV according to New York Heart Association (NYHA) classification
Second of third degree heart block regardless of the use of a pacemaker, concomitant potentially life-threatening arrhythmia or symptomatic arrhythmia
Clareo Health | Efficacy and Safety of Valsartan/Amlodipine in Patients With Mild to Moderate Essential Hypertension
